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Abstract
We have examined the interaction of the human immunodeficiency virustype 1 fusion peptide (23 amino acid residues) and
of a Trp-containing analog with vesicles composed of dioleoylphosphatidylcholine, dioleoylphosphatidylethanolamine and
cholesterol (molar ratio, 1:1:1). Both the native and the Trp-substituted peptides bound the vesicles to the same extent and
induced intervesicular lipid mixing with comparable efficiency. Infrared reflection^absorption spectroscopy data are
compatible with the adoption by the peptide of a main L-sheet structure in a cospread lipid/peptide monolayer. Cryo-
transmission electron microscopy observations of peptide-treated vesicles reveal the existence of a peculiar morphology
consisting of membrane tubular elongations protruding from single vesicles. Tryptophan fluorescence quenching by
brominated phospholipids and by water-soluble acrylamide further indicated that the peptide penetrated into the acyl chain
region closer to the interface rather than into the bilayer core. We conclude that the differential partition and shallow
penetration of the fusion peptide into the outer monolayer of a surface-constrained bilayer may account for the detected
morphological effects. Such single monolayer-restricted interaction and its structural consequences are compatible with
specific predictions of current theories on viral fusion. ß 2000 Elsevier Science B.V. All rights reserved.
Keywords: Membrane fusion; Viral fusion; Human immunode¢ciency virustype 1; Fusion peptide; Peptide^lipid interaction; Peptide
conformation
1. Introduction
Viral and cellular membrane fusion events are
mediated by specialized membrane proteins that
help in overcoming the energetic barrier associated
with the process [1,2]. Current models for the mech-
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anism of viral spike-mediated fusion involve the hy-
drophobic fusion peptide region that inserts into the
target membrane [1,3]. In human immunode¢ciency
virustype 1 (HIV-1), the fusion peptide is located at
the N-terminus of the gp41 transmembrane subunit
of the envelope protein [4^7].
Several ¢ndings, including mutational analysis,
support the direct involvement of this conserved seg-
ment of about 25 amino acids in HIV-1 fusion in
vivo [5^7]. One important and unsolved issue is to
establish whether the insertion of this sequence rep-
resents only a way to initially anchor the spike com-
plex to the target membrane or if, in addition, the
interaction of the peptides induces some kind of bi-
layer perturbation necessary for merging the viral
and cell membranes [3,8]. Pioneering in vitro studies
by Rafalski et al. [9] demonstrated the capacity of
this sequence to bind and destabilize negatively
charged model membranes composed of 1-palmito-
yl-2-oleoyl-sn-glycero-3-phosphoglycerol. Since then
several groups have published results that con¢rm
and extend those observations [10^14].
The initial interaction and ¢nal conformation
adopted by the HIV-1 fusion peptide in membrane
bilayers appears to be governed by a plethora of
experimental factors. Thus, synthetic sequences rep-
resenting di¡erent sections of the gp41 N-terminus
have been shown to interact with model membranes
while adopting di¡erent conformations. Sequences
representing the ¢rst 13 and 16 amino acids at
gp41 N-terminus are mainly K-helical at low doses
in neutral vesicles [15]. For even longer (23-residue)
sequences, a predominant K-helical conformation has
been shown in negatively charged vesicles and mi-
celles [9,13,16] and in erythrocyte membranes at
low doses [11]. However, under conditions allowing
membrane fusion in vesicular systems (e.g. anionic
and neutral vesicles containing increasing peptide
loads) the 23-residue peptides adopt predominant
L-type conformations [11,13,17^19]. For even longer
(33-mer) versions of the peptide, mainly L-type con-
formations have been detected in bilayers composed
of anionic phospholipids [20,21]. More recently,
Schwarz and Taylor [22] have reported monolayer
results also consistent with the existence of di¡erent
structures in 23-residue peptides depending on the
peptide load and monolayer compression.
Nieva et al. [17] and Pereira et al. [18] showed that
a sequence of 23 amino acid residues at the N-termi-
nus of HIV-1 gp41 has the capacity to destabilize
large unilamellar vesicles made of an equimolar mix-
ture of dioleoylphosphatidylcholine (DOPC), diole-
oylphosphatidylethanolamine (DOPE) and cholester-
ol (CHOL). In contact with these membranes the
peptide adopts a predominantly extended conforma-
tion. No alternative conformations are detected in
this system by varying the peptide dose [18]. Kinetic
analysis further suggests that the peptide acts as an
agent that confers instability to membranes so that
fusion can occur [13,17]. This implies that the L-
structure or a precursor leading to its formation
must be able to alter the local properties of the mem-
brane in order to produce the detected perturbations.
More recently, we have demonstrated by means of
cryo-transmission electron microscopy (cryo-TEM)
of diluted vesicles the formation of non-lamellar li-
pidic aggregates during the time course of lipid mix-
ing induced by the peptide [23]. The cryo-TEM tech-
nique had previously been used for monitoring
structural changes in liposomes supporting fusion
[24^28] and was also quite successful in detecting
the morphology changes experienced by vesicles in-
teracting with the HIV-1 fusion peptide.
In the present study we attempt to elucidate the
molecular mechanism underlying the membrane ac-
tivity of the HIV-1 fusion peptide under conditions
inducing the adoption of a predominantly L-type
conformation. The structure of the peptide in lipid
monolayers at the air^water interface has been eval-
uated over a wide range of lateral pressures by infra-
red re£ection^absorption spectroscopy (IRRAS). In
addition, we have made use of the invaginated mor-
phology present in DOPC:DOPE:CHOL extruded
vesicles in order to infer the location of the peptide
initially partitioning into the membrane. Loss of in-
vagination in extruded large unilamellar vesicles
(LUV) has been previously used to test changes in
internal vesicle volume and monolayer areas [29,30].
In this study, we have focused our attention on the
fraction of the peptide-treated vesicles remaining iso-
lated or at the periphery of large lipidic aggregates.
Consistent with a preferential increase of the external
monolayer surface under isotonic conditions, the in-
vagination disappears in peptide-treated vesicles. Trp
£uorescence was subsequently used to probe the
depth of peptide insertion into the membrane. For
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this purpose the phenylalanine in position 8 was sub-
stituted by a tryptophan residue, the resulting pep-
tide F8W being equally active as the original one in
vesicle destabilization and fusion. The peptide was
shown to insert close to the interface and promoted
the formation of protrusions in the surface-restricted
bilayer of isolated vesicles. These ¢ndings are dis-
cussed in relation to a putative role of fusion pep-
tides within the spike complex that mediates the viral
fusion event.
2. Materials and methods
DOPC, DOPE, dipalmitoylphosphatidylcholine
(DPPC), acyl chain-perdeuterated dipalmitoyl-
phosphatidylcholine (DPPC-d62), dipalmitoylphos-
phatidylethanolamine (DPPE) and the brominated
phospholipids 1-palmitoyl-2-stearoyl(6,7)dibromo-
sn-glycero-3-phosphocholine (Br6-PSPC) and 1-pal-
mitoyl-2-stearoyl(11,12)dibromo-sn-glycero-3-phos-
phocholine (Br11-PSPC) were purchased from Avanti
Polar Lipids (Birmingham, AL, USA). CHOL was
obtained from Sigma (St. Louis, MO, USA). All
other reagents were of analytical grade. The sequen-
ces representing the 23 amino acids at the N-termi-
nus of the HIV-1 gp41 [18] were synthesized as their
C-terminal carboxamide and puri¢ed (estimated
homogeneity s 90%) by Quality Controlled Bio-
chemicals, Inc. (Hopkinton, MA, USA). Peptide
stock solutions were prepared in dimethyl sulfoxide
(DMSO, spectroscopy grade).
LUV consisting of DOPC, DOPE and CHOL
(molar ratio, 1:1:1) were prepared according to the
extrusion method of Hope et al. [31] in 5 mM
HEPES, 100 mM NaCl (pH 7.4). Lipid concentra-
tions of liposome suspensions were determined by
phosphate analysis [32]. The mean diameter of
DOPC/DOPE/CHOL vesicles was 130 nm as esti-
mated by quasielastic light scattering using a Mal-
vern Zeta-Sizer instrument.
Membrane lipid mixing was monitored using the
resonance energy transfer assay, described by Struck
et al. [33]. The assay is based on the dilution of the
£uorescent probes N-(7-nitrobez-2-oxa-1,3-diazol-4-
yl) phosphatidylethanolamine (N-NBD-PE) and N-
(lissamine Rhodamine B sulfonyl) phosphatidyletha-
nolamine (N-Rho-PE). Dilution due to membrane
mixing results in an increase in N-NBD-PE £uores-
cence. Vesicles containing 0.6 mol% of each probe
were mixed with unlabeled vesicles at a 1:4 ratio.
The NBD emission was monitored at 530 nm with
the excitation wavelength set at 465 nm. A cuto¡
¢lter at 515 nm was used between the sample and
the emission monochromator to avoid scattering in-
terferences. The £uorescence scale was calibrated
such that the zero level corresponded to the initial
residual £uorescence of the labeled vesicles and the
100% value to complete mixing of all the lipids in the
system. The latter value was set by the £uorescence
intensity of vesicles, labeled with 0.12 mol% each of
the £uorophores, at the same total lipid concentra-
tion as in the fusion assay.
The amount of membrane-bound peptide was esti-
mated by monitoring the £uorescence of the Trp res-
idue in the F8W analog. By following a previously
published procedure [18,34], unbound peptide was
separated from bound peptide by ultracentrifugation
in D2O bu¡er. Floated membranes containing bound
peptide were solubilized with 2 mM octaethylenegly-
col monododecyl ether (C12E8) to minimize the scat-
tering contribution of membranes to Trp £uores-
cence. The Trp signal at 333 nm was normalized
for the amount of co-£oating lipid which was simul-
taneously quanti¢ed also by means of spectro-
£uorimetry. To that end, we used the same liposomes
as for the lipid mixing assay containing a fraction
(20%) labeled with 0.6 mol% of N-NBD-PE and N-
Rho-PE. In addition to lipid quanti¢cation, NBD
and Rho £uorescence measurements provided veri¢-
cation of complete vesicle solubilization by C12E8.
The samples for cryo-TEM were prepared follow-
ing two di¡erent protocols. In one protocol the pep-
tide and the liposomes were mixed under continuous
stirring at 37‡C. At de¢ned post-mixing times, drop
samples were collected from the mixtures and applied
to holey carbon ¢lms, quickly blotted and frozen in
liquid ethane at 3180‡C, so that the vesicles were
preserved in vitreous ice. Alternatively, liposome^
peptide mixtures prepared in D2O bu¡er were £oated
as described before. In brief, the mixtures were incu-
bated for 30 min at 37‡C, then overnight at room
temperature and subsequently subjected to ultracen-
trifugation (600 000Ug) for 2 h in D2O bu¡er. Sam-
ples collected from the top (£oating fraction) were
subsequently applied to the holey carbon ¢lms as
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in the previous case. The frozen grids were kept
under liquid nitrogen until used. Electron micro-
graphs were obtained using a Jeol 1200EX II oper-
ated at 120 kV and equipped with a GATAN-626
cold stage and a GATAN anticontaminator. Images
were obtained with a nominal magni¢cation of
U50 000 and an underfocus of 15 000^20 000 Aî ,
and recorded on Kodak SO-163 ¢lm developed at
full strength for 12 min in D-19 developer.
For IRRAS monolayer experiments an equimolar
solution of DPPC-d62/DPPE/CHOL was prepared in
chloroform:methanol (4:1, v:v) at a total concentra-
tion of V2 mg/ml. Phospholipids with saturated acyl
chains were chosen for monolayer studies due to
their greater ¢lm stability when compared to their
unsaturated counterparts. A 1 mg/ml peptide solu-
tion was prepared in DMSO. Appropriate amounts
of each solution were mixed to yield a total lipid to
peptide molar ratio of 14:1. A subphase of 5 mM
Tris, 100 mM NaCl, 2 WM EDTA was prepared in
D2O, pDW7.4. A D2O-based subphase was used for
the IRRAS measurements to avoid interference from
the H2O bending mode at 1640 cm31 and to lessen
the e¡ects of the rotational^vibrational modes of
H2O vapor in the same spectral region. Details of
the IRRAS trough and optical set-up have been de-
scribed elsewhere [35]. The temperature of the sub-
phase was held at 21.5 þ 0.5‡C. Spreading volumes
ranged from V8.0 Wl for the cospread lipid/peptide
¢lms to V14.0 Wl for the pure peptide ¢lms. This
resulted in initial surface pressure values of 0 mN/
m at a maximum surface area of V89 cm2. After an
initial relaxation period of 1 h, ¢lms were intermit-
tently compressed over a 3^4 h period until the de-
sired surface pressure was reached. IRRAS spectra
were acquired using a Bio-Rad FTS 40A spectrom-
eter (Cambridge, MA, USA) equipped with an MCT
detector. The experiments were conducted at a 35‡
angle of incidence (angle between the incoming beam
and surface normal). A shuttle device was employed
to compensate for atmospheric water vapor. Typi-
cally eight blocks of 128 scans each were acquired
at 4 cm31 resolution, co-added, apodized with a tri-
angular function, and Fourier-transformed with one
level of zero-¢lling to yield spectra encoded at 2 cm31
intervals. IRRAS spectra are presented as re£ec-
tance^absorbance (RA) versus wavenumber. RA is
de¢ned as 3log(R/R0), where R is the re£ectivity of
the ¢lm-covered surface and R0 is the re£ectivity of
the ¢lm-free surface. When necessary residual water
vapor was subtracted from spectra. Peak positions
were determined using a center of gravity algorithm
written at the National Research Council of Canada.
The depth of peptide penetration into the mem-
brane was evaluated using the analog of the fusion
peptide containing the F8W substitution. Quenching
of Trp £uorescence by the hydrophobic matrix-resid-
ing bromolipids was assayed as described by Bolen
and Holloway [36]. Quenching by the water-soluble
acrylamide was carried out following the methodol-
ogy described by De Kroon et al. [37] and Moro et
al. [38]. In both assays, lipid^peptide mixtures (1 WM
peptide, 100 WM lipid) were incubated at 37‡C for 10
min and then at room temperature for 1 h before
data acquisition. In the case of the bromolipid assay,
either Br6-PSPC or Br11-PSPC was used instead of
DOPC in target vesicles. Corrected Trp emission
spectra were acquired in a Perkin-Elmer MPF-66
spectro£uorimeter. Five spectra were currently aver-
aged from each sample. In the acrylamide experi-
ments Trp emission was recorded at the ¢xed wave-
length of 345 nm. Excitation was set at 295 nm in
order to reduce acrylamide absorbance. Emitted £uo-
rescence at increasing concentrations of acrylamide
was corrected for dilution, scatter contributions and
absorptive screening by acrylamide [37]. Data were
analyzed according to the Stern^Volmer equation for
collisional quenching:
F0=F  1 K svQ
where F0 and F are the £uorescence intensities in the
absence and presence of the quencher, Q, and Ksv is
the Stern^Volmer quenching constant. In the range
of acrylamide concentrations used (1^60 mM) the
Stern^Volmer plots did not deviate from linearity.
3. Results
3.1. Peptide-induced intervesicular lipid mixing
The activity of the parental HIV-1 fusion peptide
was comparatively studied together with the F8W
substitution-containing analog in terms of their abil-
ity to bind lipid bilayers and induce lipid mixing.
This was intended to establish a quantitative rela-
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tionship between the morphological changes detected
in peptide-treated DOPC/DOPE/CHOL vesicles and
the peptide dose required in the membrane to induce
such alterations. As shown in Fig. 1A, the £uorescent
peptide analog containing the F8W substitution was
as e¡ective as the parental HIV-1 sequence in pro-
moting lipid mixing over a wide range of peptide
concentrations. This observation con¢rms the func-
tional equivalence of both sequences.
The use of a £uorescent analog allows, among
other things, an estimation of the amount of mem-
brane-bound peptide by monitoring the £uorescence
of the Trp residue (see Section 2). In Fig. 1B the
amount of bound peptide per lipid, as estimated
from Trp £uorescence, is plotted together with the
binding data deduced from Fourier transform infra-
red (FTIR) measurements performed on £oated
DOPC/DOPE/CHOL vesicles that had been treated
with variable doses of the parental peptide [18]. In
those samples, the ratio of the amide I absorbance at
1625 cm31 (absorption of the extended structure of
the peptide) to that at 1734 cm31 arising from the
CNO stretching vibration of the phospholipid ester
bonds is proportional to the peptide-to-lipid ratio in
the membrane. As shown in Fig. 1B, both sets of
data can be ¢tted to a single curve that shows satu-
ration at values corresponding roughly to 35 lipids
per bound peptide.
3.2. Peptide conformation in a lipidic environment
The IRRAS spectrum of the lipid carbonyl and
amide I region for a cospread lipid (DPPC-d62/
DPPE/CHOL)/peptide monolayer on D2O bu¡er is
shown in Fig. 2. The presence of the amide I vibra-
Fig. 1. (A) Extent of membrane lipid mixing of DOPC/DOPE/
CHOL (1:1:1) LUV induced by the HIV-1 fusion peptide
(open circles) and its F8W analog (¢lled circles) as a function
of lipid-to-peptide molar ratio. Vesicle concentration was 100
WM. (B) Saturation curves of the amount of peptide bound per
lipid in £oated DOPC/DOPE/CHOL (1:1:1) LUV as a function
of the added peptide-to-lipid ratio. The peptide was added to
LUV (1 mM) at di¡erent peptide-to-lipid ratios, incubated for
30 min at 37‡C and then overnight at room temperature. The
formed peptide^lipid complexes were subsequently isolated from
the £oating fractions after ultracentrifugation in D2O bu¡er.
Filled circles: amount of F8W analog bound per lipid as esti-
mated from Trp £uorescence associated with the £oating
vesicles ; open circles: I1625 cm31=I1734 cm31 ratio as estimated
from FTIR data of HIV-1 fusion peptide associated with
vesicles [18].
Fig. 2. IRRAS spectrum of (DPPC-d62/DPPE/CHOL)/peptide
monolayer (total lipid-to-peptide molar ratio, 14:1) on D2O
bu¡er at a surface pressure of 8 mN/m. The inset displays IR-
RAS spectrum of pure peptide monolayer under the same con-
ditions.
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tional mode at 1623 cm31 is indicative of deuterium-
exchanged L-sheet secondary structure. Minor contri-
butions to the amide I band contour in the 1640^
1660 cm31 region may result from random coil or
helical structure. The absence of an amide II band,
in the 1550 cm31 region (not shown), signi¢es that
the hydrogen^deuterium exchange is essentially com-
plete. The lipid carbonyl band is observed at V1735
cm31.
The inset in Fig. 2 displays the IRRAS spectrum
of a pure peptide monolayer. The predominant
amide I band is observed at 1620 cm31, with a
shoulder in the 1640^1650 cm31 region, and a less
intense component at V1690 cm31. The presence of
both high and low frequency components (1690,
1620 cm31) and their relative intensities indicate
that the peptide forms antiparallel L-sheet structures
at the air^D2O interface. The less intense component
may be just discernible in the binary monolayer spec-
trum at V1690 cm31, however, the low signal to
noise level makes it di⁄cult to assign this band
with certainty. The lower frequency observed for
the main amide I peak of the pure peptide monolayer
compared to the binary system suggests a slightly
more extended or aggregated L-sheet-type structure
for the former [39]. In the inset, residual amide II
band intensity is observed between 1500 and 1550
cm31 indicating that a small number of peptide
groups have not been deuterium-exchanged. These
¢ndings would be consistent with the existence of
an interaction between lipid and peptide in the bina-
ry system. Moreover, they indicate that, most likely
as a consequence of such an interaction, pure peptide
di¡ers structurally from the peptide associated with
the lipid monolayer.
Additional evidence that the spectrum in Fig. 2 is
characteristic of peptides interacting with hosting lip-
ids comes from the fact that the amide I band posi-
tion for this lipid/peptide monolayer does not change
over a pressure range from 6 to 27 mN/m (data not
shown). If the peptide existed on the surface in lipid-
free separated domains, we would expect a lower
amide I frequency (similar to the same position as
the pure peptide). This also indicates that under
those measuring conditions, altering the monolayer
lateral pressure did not induce any appreciable con-
formational change. Pereira et al. [18] found for
DOPC:DOPE:CHOL LUV that the structure
adopted by the peptide at equilibrium was mainly
an extended one at peptide-to-lipid molar ratios
ranging from 1:800 to 1:10. Both ¢ndings suggest
that this lipid matrix containing the peptide repre-
sents a homogeneous system in the sense that the
peptide conformation is locked into one single struc-
ture under a variety of membrane conditions. Con-
sistency of secondary structure in the bilayer versus
monolayer environments is not necessarily antici-
pated as peptides and proteins have been previously
shown to have di¡erent conformations in these two
di¡erent systems [40].
3.3. E¡ect on vesicle morphology
Cryo-TEM micrographs of vitri¢ed DOPC/DOPE/
CHOL unilamellar vesicles obtained from £oating
fractions (Fig. 3) showed a majority of vesicles (ap-
prox. 90%) whose stomatocyte-like morphology sug-
gested the existence of an initial invaginated state.
The remaining vesicle population (approx. 10%) con-
sisted of spherical vesicles and, therefore, the pres-
ence of morphologies others than spherical or invag-
inated in our DOPC/DOPE/CHOL unilamellar
vesicles obtained through extrusion [31] can be ex-
cluded. This observation is critical to infer the local-
ization of the membrane-partitioning peptide
through the loss of the initial invagination state
Fig. 3. Cryo-TEM micrograph of control extruded LUV of
DOPC/DOPE/CHOL (1:1:1) showing stomatocyte-like mor-
phology. Arrowheads: vesicles oriented showing the open neck.
Arrows: vesicles oriented such that the symmetry axis is per-
pendicular to the projection plane. Bar: 100 nm.
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(see below). A detailed view of a representative ex-
ample of such predominantly invaginated non-spher-
ical vesicles is shown in Fig. 4a. The picture, ob-
tained from a sample vitri¢ed at 37‡C, illustrates
the invaginated morphology in which the rounded
open neck connecting the internal and external
vesicles can be easily discerned (arrowhead).
It is well established that the extrusion process
used to generate LUV renders non-spherical systems
[24,29]. As discussed by Mui et al. [30], the shear
tensions during the process may generate di¡erences
between internal and external monolayer areas,
whose range may be speci¢c for the lipid composi-
tion and other experimental conditions used during
the extrusion procedure. The DOPC/DOPE/CHOL
(1:1:1) LUV samples that we obtained through ex-
trusion (Fig. 3) structurally resemble the DOPC/dio-
leoylphosphatidylglycerol (DOPG) (9:1) and DOPC/
DOPG/CHOL (6:1:3) LUV samples obtained by
Mui et al. [30] in that they mainly consist of stoma-
tocytes. These authors showed that such an initial
condition could be used to test in LUV the morpho-
logical consequences of generating a transbilayer
area asymmetry. They demonstrated that increasing
the external monolayer surface area by inducing
transbilayer transport of phospholipids eventually
transforms invaginated LUV into beaded-tubular
structures or spherical structures with one or more
membrane protrusions.
Starting from an analogous invaginated LUV sam-
ple, we have studied here the morphological e¡ect of
HIV-1 peptide addition. Following the reasoning of
Mui et al. [30], we expected to infer from changes in
the morphology of our invaginated LUV whether the
peptide did or did not preferentially partition into
the external monolayer increasing its surface. If the
peptide instantaneously redistributed among both
monolayers and/or adopted a transmembrane orien-
tation it would not di¡erentially a¡ect monolayer
surfaces, and morphology changes would not be ex-
pected. As shown in Fig. 4b^e a morphology consist-
C
Fig. 4. Cryo-TEM micrographs of LUV of DOPC/DOPE/
CHOL (1:1:1) vitri¢ed at various times after peptide addition
(peptide-to-lipid molar ratio 1:10, i.e. saturating conditions)
showing membrane protrusions. (a) Detailed view of a LUV of
DOPC/DOPE/CHOL (1:1:1) before peptide addition (time = 0)
showing invaginative processes, the arrowhead indicates the
open rounded neck. (b, c) Time = 9 s. (d) Time = 55 s. (e) Pep-
tide-treated vesicles after £otation in D2O bu¡er, in this case
vesicles (1 mM) were mixed with the peptide as before at 37‡C,
incubated for 30 min and then overnight at room temperature
before ultracentrifugation in D2O bu¡er (2 h at 600 000Ug).
Bars: 100 nm. These micrographs are representative examples
of nine processed samples and 47 di¡erent grid areas explored.
BBAMEM 77876 26-7-00
A. Agirre et al. / Biochimica et Biophysica Acta 1467 (2000) 153^164 159
ing of membrane protrusions and beaded tubes could
be observed in HIV-1 fusion peptide-treated vesicles.
In fact only 30% of the non-aggregated vesicles re-
mained invaginated in those samples. Morphological
changes re£ected in Fig. 4b^e compared to Fig. 4a
are consistent with the induction by the peptide of a
preferential increase of the external monolayer area,
with little or no change in vesicle volume [30].
It must be pointed out that these micrographs cor-
respond to grid regions where single vesicles could be
discerned either isolated or at the edge of large ag-
gregates that were also formed as a consequence of
the peptide interaction [23]. Those aggregates show a
characteristic compact morphology consisting of
highly bent lamellae and multiple attachments, and
represent probably a non-lamellar organization of
the peptide^lipid complexes. Formation of those
structures must involve multiple fusion events mak-
ing it possible that membranes of di¡erent sidedness
become contiguous, a process that by itself could
relieve transbilayer stress. We must thus caution
that the morphology of large fused vesicles incubated
for long times, such as those shown in Fig. 4e, could
have originated from multiple fusion events.
The IRRAS spectrum depicted in Fig. 2 for the
peptide and a lipid monolayer was acquired at a
peptide-to-lipid molar ratio of 1:14, equivalent to a
1:28 molar ratio in a bilayer system in which only
one monolayer contained the peptide. Under the
conditions used to evaluate morphology changes in
Fig. 4 vesicles became saturated at about 1:35 (see
Fig. 1). So the cryo-TEM and IRRAS experiments
were conducted at comparable peptide-to-lipid molar
ratios. This, together with the fact that the same sec-
ondary structure is observed for bilayers and mono-
layers, indicates that the peptide structure inferred
from IRRAS experiments is likely to re£ect the struc-
ture that the peptide interacting with vesicles even-
tually adopts in cryo-TEM samples.
Taken together, the IRRAS and cryo-TEM results
suggest that in our system it is the initial di¡erential
partitioning of the peptide into the external mono-
layer of isolated vesicles that induces di¡erences be-
tween the surface areas of the two monolayers. This
phenomenon could be at the origin of the dramatic
changes in vesicle morphology described. It should
be noted that this peptide e¡ect would only occur in
surface-restricted systems such as the closed vesicles
used in this study, where the di¡erence in surface
areas between the inner and outer monolayers can-
not be balanced through the recruitment of lipids
[29,30].
3.4. Depth of penetration
The peptide containing the F8W substitution was
also used to estimate the depth of its penetration into
the bilayer. Control experiments performed in the
presence of this Trp analog demonstrated the ability
of this sequence to promote a similar morphology to
that induced by the parental peptide in DOPC/
DOPE/CHOL vesicles (data not shown). Results dis-
played in Figs. 5 and 6 provide strong evidence that
the fusion peptide penetrates into the membrane to
the level of the acyl chains.
Fig. 5. (A) Fluorescence emission spectra of the F8W analog in
bu¡er (1), and incubated with DOPC/DOPE/CHOL LUV (2).
Vesicle concentration was 0.1 mM and the peptide-to-lipid ratio
1:100. (B) Fluorescence emission spectra of F8W analog incu-
bated with LUV (0.1 mM) containing brominated phospholip-
ids: (1) DOPC/DOPE/CHOL; (2) Br6-PSPC/DOPE/CHOL; (3)
Br11-PSPC/DOPE/CHOL. Peptide-to-lipid ratio as in A. Lipid^
peptide mixtures were incubated at 37‡C for 10 min and then
at room temperature for 1 h before data acquisition.
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In Fig. 5A the emission spectra of the peptide in
solution and in the presence of DOPC/DOPE/CHOL
large unilamellar vesicles are compared. Trp emission
intensity was signi¢cantly enhanced in the presence
of the vesicles. This e¡ect suggests that the Trp res-
idue in the presence of vesicles was ‘sensing’ a less
polar environment which is indicative of peptide pen-
etration into the hydrophobic core of the bilayer.
The bilayer level to which the peptide penetrated
can be deduced from the spectra displayed in Fig.
5B Both Br6-PSPC- and Br11-PSPC-containing
LUV quenched Trp £uorescence to some extent,
but the former vesicles showed a higher quenching
e⁄ciency. Bromine atoms quench by a short-range
process that requires a close approach to the £uoro-
phore [36]. This would mean that the Trp residue
must be located closer to the C6-C7 than to the
C11-C12 position within the acyl chain region of the
bilayer.
Peptide penetration was further con¢rmed by the
results obtained using the aqueous quencher acryl-
amide (Fig. 6). We selected this particular quencher
since non-polar £uorophores embedded in the bilayer
are not quenched by it [38]. For the peptide in bu¡er
the Stern^Volmer quenching constant (Ksv) obtained
from the plot depicted in the ¢gure was 22.9 M31. In
the presence of DOPC/DOPE/CHOL LUV, the ob-
tained Ksv values were 21.4 M31 for the water-solu-
ble Trp analog N-acetyl-L-tryptophanamide and 9.8
M31 for the HIV-1 fusion peptide. Since N-acetyl-L-
tryptophanamide is fully accessible to acrylamide
[41], those data indicate that the accessibility of the
aqueous quencher to the Trp residue in the fusion
peptide in the presence of vesicles was markedly re-
duced, a fact that is consistent with penetration of
the peptide into the matrix of the bilayer.
4. Discussion
4.1. Interaction of the HIV-1 fusion peptide with
membranes
Taking into account the experimental results in
this work, i.e. adoption by the peptide of an ex-
tended structure in lipid monolayers, induction of
membrane protrusions in extruded vesicles, and pen-
etration into the hydrophobic milieu of the bilayer,
we can suggest a picture of how the HIV-1 fusion
peptide interacts with DOPC/DOPE/CHOL mem-
branes. Our suggestion is twofold.
First we propose that the interaction of the peptide
adopting an extended structure is restricted to the
outer membrane monolayer. The IRRAS data show
that the peptide adopts the same L secondary struc-
ture in lipid monolayers as it does in vesicles [18]. In
addition, the membrane protrusions in Fig. 4 would
be consistent with a di¡erential increase in the area
of the vesicle external monolayer, caused by the pref-
erential partition of the externally added peptide to
surface-constrained bilayers (i.e. vesicle bilayers). In
other words, loss of the initial invagination state is
caused by the preferential insertion of the peptide in
the external monolayer of the vesicle. To our knowl-
edge this morphological transition induced in vesicles
by a viral fusion peptide had not been previously
described.
Second, we suggest that the peptide remains close
to the lipid^water interface when inserted into the
membrane. Assuming the bilayer and hydrocarbon
chain region thicknesses to be 50 and 30 Aî respec-
tively, and the bromine distances from the bilayer
Fig. 6. Stern^Volmer plot of Trp £uorescence quenching of
F8W analog by increasing concentrations of acrylamide, in so-
lution (open circles) and in the presence of 100 WM DOPC/
DOPE/CHOL LUV (¢lled circles) (peptide-to-lipid molar ratio,
1:100). A mixture of N-acetyl-L-tryptophanamide in the pres-
ence of liposomes (triangles) was used to obtain a reference
curve corresponding to 100% solvent-exposed residues.
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center 11 Aî for 6,7 labels and 6.5 Aî for 11,12 labels
[42], the results in Figs. 5 and 6 would be consistent
with a location of the Trp residue in the acyl chain
region closer to the interface (V4 Aî ) than to the
bilayer core (V11 Aî ). The shallow penetration of
the peptide in one of the monolayers could induce
the di¡erential surface increase that is at the origin of
the loss of the invaginated morphology of the
vesicles.
Preferential insertion of a fusion peptide into the
external monolayer has been previously demon-
strated by Brunner [43] for the in£uenza fusion pep-
tide. This author showed by means of hydrophobic
photolabeling techniques that the fusion peptide at
the N-terminus of bromelain-solubilized ectodomain
of in£uenza hemagglutinin contacts only the outer
lea£et of the liposome bilayer. More recently, using
micropipette aspiration and video microscopy of
large unilamellar vesicles, Longo et al. [44] have dem-
onstrated that the interaction of a synthetic peptide
representing the N-terminus of in£uenza hemaggluti-
nin results in a large increase in membrane surface
area. Incorporation of the peptide is subsequently
followed by permeation through discrete pores and
eventual rupture of the permeability barrier. Our re-
sults in this and previous works would be consistent
with a similar behavior of the HIV-1 fusion peptide.
The morphological data described here are compat-
ible with membrane area expansion speci¢cally ex-
erted on the external monolayer. Leakage assays
demonstrate that the peptide permeabilizes isolated
vesicles [17,18] and the very existence of the aggre-
gation and fusion processes taking place thereafter
[23] seems to indicate that the peptide is able to per-
turb the lipid^water interface when it associates with
membranes. Breaking down the continuity of mono-
layers may result in some exposure of the hydropho-
bic interior to the surrounding water which would in
turn promote aggregation and fusion in vesicle sus-
pensions. Membrane destabilization by peptides ly-
ing parallel to the membrane plane, and located in
the outer monolayer in a ‘carpet-like’ fashion, has
been proposed in several instances for widely di¡er-
ent peptides and proteins [45^47].
4.2. Implications for the fusion mechanism
In a recent report on membrane fusion catalyzed
by in£uenza hemagglutinin Chernomordik et al. [48]
have proposed the involvement of a structural inter-
mediate consisting of a ring of activated spikes that
would restrict the £ux of the enclosed lipids. Several
indications suggest that HIV-1 gp41 activation is
highly reminiscent of hemagglutinin activation
[49,50]. If this is the case, it might be possible that
one of the roles of the activated spike complex in
promoting HIV-1 fusion would be to restrict lipid
lateral di¡usion in a de¢ned area of the target mem-
brane. If the HIV-1 fusion peptide is to insert into a
bounded section of the target membrane, one may
speculate on the consequences that such an interac-
tion may have for the bilayer structure.
According to the experimental results described in
this work, the local interaction of the HIV-1 gp41 N-
terminal sequence with the target membrane might
induce an increase in the external lea£et surface (cis
contacting monolayer). Membrane stress might then
be relaxed by two mechanisms operating simultane-
ously. The bilayer could change its shape giving rise
to local and transient evaginations, and the internal
monolayer (trans monolayer) might become stretched
and locally thinned as the peptide was preferentially
inserted into the external monolayer.
The hypothetical membrane destabilization de-
scribed may reasonably be integrated within the
body of the ‘stalk mechanism’ theory of fusion
[51,52]. The stalk is a transient lipidic intermediate
locally connecting the cis monolayers of apposed
membranes. This intermediate is proposed to evolve
towards hemifusion intermediates that eventually
form the fusion pore, the ¢nal structure connecting
both sides of the membranes in apposition and al-
lowing mixing of aqueous contents. Stalk formation
requires local destabilization of the contacting mono-
layers and exposure of hydrophobic groups. It has
been argued that membrane adhesion might be facili-
tated at the peak of localized membrane protrusions
[53]. Our experimental results indicate that the pep-
tide insertion within a surface-constrained area might
constitute a factor that would help in the formation
of those protruding structures, and consequently also
in the formation of the stalk.
According to the ‘modi¢ed stalk’ theory for fusion
[28,52], the structural intermediates that follow stalk
formation are trans monolayer contacts (TMCs), or
local points of restricted hemifusion. Rupture of the
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single bilayer diaphragm in TMCs would constitute
the limiting step in the formation of the interlamellar
attachments or fusion pores. These authors propose
that viral fusion peptides could facilitate the forma-
tion of fusion pores by lowering the rupture tension
of the TMC diaphragm. For instance, a putative
mechanism, suggested by Siegel and Epand [28],
might be a peptide-induced reduction of the lipid
cohesion through a local change of bilayer thickness.
Our experimental work suggests that, within surface-
restricted bilayers, HIV-1 fusion peptide insertion
into cis monolayers might result in concomitant thin-
ning of trans monolayers, a process that would likely
reduce their cohesion. So, a TMC bilayer diaphragm
composed of stressed trans monolayers would prob-
ably be more prone to rupture and fusion pore for-
mation would become easier/faster.
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